POSTER PRESENTATION

Open Access

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein

Caroline Jochems^{1*}, Jo A Tucker¹, Matteo Vergati¹, Benjamin Boyerinas¹, James L Gulley^{1,2}, Jeffrey Schlom¹, Kwong-Yok Tsang¹

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Purpose

The MUC1 tumor-associated antigen is overexpressed in the majority of human carcinomas and several hematologic malignancies. Much attention has been paid to the hypoglycosylated VNTR region of the N-terminus of MUC1 as a vaccine target, and recombinant viral vector vaccines are also being evaluated that express the entire MUC1 transgene. While previous studies have described MUC1 as a tumor-associated tissue differentiation antigen, numerous studies have now determined that the C-terminus of MUC1 (MUC1-C) is an oncoprotein, and its expression is an indication of poor prognosis in numerous tumor types.

Experimental design

We report here the identification of seven potential CD8+ cytotoxic T lymphocyte epitopes of MUC1: five in the C-terminus and two in the VNTR region, and have identified enhancer agonist peptides for each of these epitopes. These epitopes span HLA-A2 and A3 MHC class I alleles, which encompass two thirds of the population.

Results

The agonist peptides, compared to the native peptides, more efficiently (a) generate T-cell lines from the peripheral blood mononuclear cells of cancer patients, (b) enhance the production of IFN- γ by peptide-activated human T cells, and (c) lyse human tumor cell targets in an MHC-restricted manner.

Conclusions

The agonist epitopes described here can be incorporated in various vaccine platforms and for ex vivo generation of

human T cells. These studies thus provide the rationale for the T-cell-mediated targeting of the oncogenic C-terminus of MUC1, which has been shown to be an important factor in both drug resistance and poor prognosis for numerous tumor types.

Authors' details

¹Laboratory of Tumor Immunology and Biology, NCI, Bethesda, MD, USA.

²Medical Oncology Branch, NCI, Bethesda, MD, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P218

Cite this article as: Jochems et al.: Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P218.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

¹Laboratory of Tumor Immunology and Biology, NCI, Bethesda, MD, USA
Full list of author information is available at the end of the article